Symptom monitoring with electronic patient-reported outcomes during cancer treatment by Ethan Basch et al.
On 07 February 2025, a paper by Ethan Basch et al. was published in Nature Medicine, titled:
Authors: Ethan Basch, Deborah Schrag, Jennifer Jansen, Anna Wolf, Amylou Dueck et al.
A cluster-randomized trial across 52 oncology practices evaluated electronic patient-reported outcomes (PROs) in metastatic cancer care. Patients in PRO practices completed weekly symptom surveys, triggering alerts for severe or worsening symptoms.
Among 1,191 patients, survival did not differ (HR 0.99, 95% CI 0.83–1.17; P = 0.86), but PRO monitoring reduced emergency visits (HR 0.84; P = 0.03) and delayed declines in physical function (HR 0.73; P = 0.002), symptoms (HR 0.69; P < 0.001), and quality of life (HR 0.72; P = 0.001).
Patients reported improved communication (77%), greater control (84%), and high satisfaction (91%). Adherence was 91.5% (20,565/22,486 surveys completed). PRO monitoring significantly improves patient outcomes and healthcare utilization and should be standard in cancer care. Future research should prioritize symptom management and quality of life over survival.
More posts featuring Ethan Basch.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023